Introduction
With advances in modern technologies and growing understanding of cellular biology, a variety of new mechanisms and molecular antagonists are currently being pursued in the ®ght against cancer. The result of these advances has spawned dozens of new exciting small molecule agents which are slowly progressing through the arduous process of clinical trials. We attempt in this review to highlight some of the new and exciting molecules representing previously unexplored targets. While it is by no means certain that novelty in a molecular target assures that it is a good one, our reading of the current literature would suggest that the seven molecules discussed in this review represent potentially new therapies which may add to the much needed armamentarium of cancer drugs (Figure 1 ).
Proteasome inhibitor, PS-341
The 26S proteasome is the universal multi-catalytic protease, responsible for the bulk of protein turnover in all cells (Peters et al., 1998; Ciechanover, 1998; Lee and Goldberg, 1998; Spataro et al., 1998) . Researchers at Millennium have developed a selective inhibitor of the chymotryptic activity which is sucient to block cellular proteolysis. PS-341, a dipeptide boronic acid binds reversibly to the active site threonine residue, in a competitive fashion (Adams et al., 1998) . In cell culture proteasome inhibition initially leads to G2-M arrest when studied between 4 ± 8 h. Longer exposures (416 h) result in apoptoic death (Adams et al., 1999) . Extensive testing of PS-341 in a large number of tumor cell lines revealed it to be a potent inhibitor of cell growth and induction of apoptosis at low nanomolar concentrations. When compared with untransformed cells, PS-341 (and other proteasome inhibitors) demonstrated selective killing of tumor cells (Adams et al., 1999) . The mechanisms of action necessarily involve the stabilization of hundreds to thousands of proteins including short lived regulatory molecules which drive the cell cycle, tumor suppressors and growth factors. All of these actions conspire to confound cellular signals for growth, lead to a profound stress response, and induce apoptosis. It is tempting to speculate, although hard data is still required to support the hypothesis, that tumor cells, which have defective DNA repair and checkpoint machinery are more susceptible to the eects of proteasome inhibition, thus providing the basis for a therapeutic index (Orlowski et al., 1998) . Further work using PS-341 in cell culture experiments has demonstrated that it is a potent inhibitor of the activation of NF-kB, a transcription factor which has recently been implicated in tumor cell survival (Beg and Baltimore 1996; Van Antwerp et al., 1996; Wang et al., 1996) . This is achieved through the stabilization of the inhibitor protein IkB thereby preventing nuclear translocation of the active transcription factor. PS-341 has also been shown to bypass Bcl-2 cytoprotection (Herrmann et al., 1998) . Encouraged by cellular experiments, several murine and human tumor xenograft models were studied revealing potent growth inhibition (Adams et al., 1999) . DNA damaging agents which activate NF-kB, when combined with PS-341, have led to regression of tumors in animals. Following extensive pre-clinical experimentation to demonstrate that proteasome blockade is tolerated to 80% inhibition, PS-341 entered clinical trials and its activity was monitored using an ex vivo enzyme bioassay (Millennium Pharmaceuticals, Inc., Proteasome Inhibitor, PS-341, IND# 56,515, submission to the FDA, July 1998). The results to date are most encouraging. The drug is remarkably well tolerated, with few of the common toxicities observed with approved chemotherapy agents, such as myelosuppression and alopecia. The drug inhibits its biological target, the proteasome, and this pharmacodynamic endpoint has been used to guide the escalation of dose. PS-341 has shown promising biological activity in both hematological and solid tumor malignancies, although it is too early to assess the full clinical impact of these early observations. Phase II monotherapy studies will begin shortly and Phase I studies in combination with standard chemotherapy agents have just begun.
HSP 90 inhibitor, geldanamycin (17-AAG)
The benzoquinone ansamycin geldanamycin analog, bearing a 17-allyl amino moiety is currently in Phase I Clinical Trials at the National Cancer Institute . 17-AAG is a member of a larger class of related antibiotic natural products. It was thought originally to be a non-speci®c kinase inhibitor. Its molecular mechanism has recently been rede®ned where it has been shown that geldanamycin binds to the chaperone protein Hsp90 (Hickey et al., 1989) . The co-crystal structure revealed that the binding site is a hydrophobic pocket which is normally associated with interactions of denatured protein substrates (Stebbins et al., 1997) . This pocket also bears strong homology with ATP binding motifs present in bacterial DNA gyrase, suggesting a role for ATP binding of Hsp90. Further biochemical and genetic studies have shown that immobilized geldanamycin bound the glycine-rich N-terminal domain requiring ATP (Grenert et al., 1997) . Taken together, the data point to ATP/geldanamycin interactions which regulate the conformation of Hsp90 chaperone complexes with numerous protein substrates, depending on whether the nucleotide is in the triphosphate or hydrolyzed diphosphate mode ± a molecular switch.
Thus the initial observation that geldanamycin and its analogs function as non-speci®c tyrosine and serine/ threonine protein kinase inhibitors is an indirect result derived from the destabilization of the client protein bound to the chaperone Hsp90. Uncoupling of the kinases, such as src family kinases (Courtneidge and Bishop, 1982; Brugge et al., 1983) , Wee1 kinase involved in G2-M transition (Aligue et al., 1994) , receptor tyrosine kinases, PDGF, EGF (Sakagami et al., 1999) , Raf-1 kinase (Stancato et al., 1993; Wartmann and Davis, 1994) all involved in mitogenic signaling, lead to destabilization of the free protein and depletion through ubiquitin-mediated degradation by the proteasome. Additionally, cyclin dependent kinases cdk4/cdk6 (Akagi et al., 1996) , focal adhesion kinase (FAK) (Ochel et al., 1999) which regulates cellular motility and relates to tumor invasiveness have also proven to be Hsp90 partners which are disrupted and degraded upon geldanamycin treatment.
Drug development of geldanamycin as its allyl amino derivative was selected based on the drug's particular eect on Her2 positive cell lines demonstrating low nanomolar potency in the Her2 background . The ®rst Phase I trial is being conducted at Memorial Sloan Kettering, in parallel with a trial at the Royal Marsden Hospital in London. At the time of this writing it is too soon to know whether the biological antagonism of Hsp90 will prove to be therapeutically eective, but it is tempting to speculate that just like proteasome inhibition, that blockade of a fundamental and essential pathway in cells may prove to be a useful approach to induce apoptosis. Further understanding of the`house keeping' role versus the tumor antagonism role of such agents will de®ne whether a therapeutic index, and perhaps more importantly, a rationale for combination therapy with a higher therapeutic potential exists.
Histone deacetylase inhibitor, SAHA
The ®rst histone deacetylase, was cloned by Hassiq and Schreiber (1997); Taunton et al. (1996) ; Grozinger et al. (1999) and was accompanied by the simultaneous discovery of small molecule inhibitors. The enzyme is a member of a larger class of isozymes which cleave the acetyl group on the e-amino of modi®ed lysine residues on histones. This action serves to counteract the histone acetyl transferases (HAT) which add acetyl groups, producing conformational changes to enhance transcriptional activity. The deacetylation reaction modi®es chromatin and the transcriptional activity of Rb, which acts to repress the transcriptional factor E2F. Rb has also been shown to interact directly with HDAC. Kouzarides (1999) has demonstrated that E2F is acetylated and that Rb acts to recruit the deacteylase to de-repress transcription. This mechanism is just the tip of the iceberg, for other HDACs which are presumably remodeling chromatin with a variety of still unknown functions.
Importantly, a number of small molecules based on natural products (trapoxin A (Itazaki et al., 1990; Kwon et al., 1998) , trichostatin (Yoshida et al., 1995) , apcidin (Kim et al., 2000) have all been tested and shown to have anti-tumoral potential in murine models. The literature is ever expanding and revealing new mechanisms by which chromatin remodeling is regulated in part by acetylation/deacetylation reactions. Paul Marks at Memorial Sloan Kettering, working with a Columbia University chemist, Ronald Breslow, have designed a series of hydroxamic acids which are potent inhibitors of HDAC. The co-crystal structures, published last year by the Pavletich group, reveal the nature of the chelation interaction of the hydroxamic acid moiety from suberanilohydroxamic acid, SAHA, and the active site zinc atom (Finnin et al., 1999) . Trichostatin A was also co-crystallized and interacts in a similar manner (Finnin et al., 1999) .
The SAHA molecule is the ®rst HDAC inhibitor to enter clinical trials. Pre-clinical activity has shown a variety of dierent activities as a dierentiating agent in leukemic cell lines (Richon et al., 1996 (Richon et al., , 1998 and breast cancer lines. Other investigators have also demonstrated that HDAC inhibition is associated with apoptosis through suppression of IAP genes and suppression of anti-apoptotic factors in prostate cancer cells (Kwon et al., 1999) . In neuroblastoma cell lines, these inhibitors induced the caspase-3 pathway leading to apoptosis (Glick et al., 1999) .
Anti-angiogenic tubulin binding agent, Combretastatin A4 phosphate
Combretastatin A4 is a natural product, ®rst isolated from the South African tree Combretan carum . It is a lipophilic cis stilbene which binds to the same binding site of tubulin as colchicine which is a known inhibitor of tubulin polymerization . Owing to its poor aqueous solubility, Arizona State University chemist, George Pettit, synthesized combretastatin and attached a phosphate moiety to produce a water soluble pro-drug which can now be delivered systemically (Pettit and Rhodes, 1998) . The negatively charged phosphate group prevents cellular transport of the drug, however the phosphate group is readily cleaved by serum phosphatases releasing the uncharged active agent which crosses cellular membranes. Remarkably, and still not fully understood, combretastatin A4 interacts with tubulin of proliferating endothelial cells in preference to non-dividing vascular endothelial cells (Tozer et al., 1999) . Morphologic studies of tumor neo-vasculature suggest a very dierent architecture in blood vessels supporting tumor growth. It is precisely the selectivity for the tumor neovasculature, on which combretastatin acts, that provides the therapeutic index (Grosios et al., 1999; Hori et al., 1999) .
Extensive studies using subcutaneously and orthotopically implanted tumors in mice indicate that combretastatin A4 can shut down blood supply to tumors, starving the growing tumor, while maintaining normal blood¯ow in adjacent normal tissues . Combretastatin A4 disrupts the cytoskeleton of dividing endothelial cells and produces damage to the tumor vascular tissue resulting in hemorrhagic necrosis. As with most anti-angiogenic agents in development, the strategy of drug combinations with approved cytotoxic chemotherapy agents has also been explored. To this point, combretastatin A4 shows synergistic behavior with 5-FU in murine colon adenocarcinoma (Grosios et al., 2000) .
Oxigene Inc, the company developing Combretastatin A4 phosphate, recently commenced Phase I clinical trials at centers in the UK and in the US. Interim results have demonstrated that CA4P can be safely administered, given infusions every 3 weeks, and reduction of blood¯ow to tumor sites was recorded, using dynamic gadolinium enhanced MRI scanning. Within 2 h of the drug administration (452 mg/m 2 ), patients reported pain at the tumor site at concentrations commensurate with blood¯ow reduction, and consistent with the hypothesis of neo-vascular necrosis. Whether this will also prove to be of clinical bene®t awaits further analysis and continued clinical testing.
A minor-grove DNA inhibitor, ET-743
Ecteinascidin (ET-743) is a marine alkaloid derived from the Caribbean sea squirt, E Turbinata, being developed by Pharma Mar, Madrid, Spain (Rinehart et al., 1990) . The drug exhibits a potent and an unique mechanism of cytotoxicity in a variety of human cancer cell lines and xenografts including leukemia, melanoma, ovarian, sarcoma, breast and lung tumors (Jimeno et al., 1996) . Although the anti-tumor eects of ET-743 are independent of p53 status, in wild-type cells the p53 protein levels appear to be stabilized following drug treatment. Furthermore, examination of tumor cells exposed to the drug show an increase in G2-M blockade (D'Incalci, 1999) . ET-743 is believed to cause cytotoxicity by inhibiting speci®c binding of certain transcription factors to their consensus DNA promoter sequences (Broggini and D'Incalci, 1994) . Of the targets most sensitive to ET-743 include the transcription factor, NFY, and the cellular proteins GADD45 and p21 (Bonfanti et al., 1999) . NFY is a pivotal factor involved in MDR1 transcription. ET-743 has recently been reported to block the eects of NFY on MDR1 expression (Jin et al., 2000) . Levels of mismatch repair de®ciencies, seen in some cancer cells lines, are also unable to modify the eect of ET-743 whereas cells de®cient in DNA dependent protein kinase (DNA-PK) appear to be more sensitive to the drug (D'Incalci, 1999) . Recently it has been proposed that ET-743 works by inhibiting the minor groove of DNA which interferes with binding of the aforementioned transcription factors. The drug interacts with guanine at the N2 position (Pommier et al., 1996) . The carbinolamine moiety of ET-743 appears to be the site that forms covalent adducts with the DNA especially in GC-rich sequences. Other compounds that aect minor groove DNA binding such as distamycins are known to be reactive in AT-rich regions suggesting an overall gene regulation impairment by such agents (Broggini et al., 1989) . Through DNA minor groove alkylation, ET-743 also induces topoisomerase I mediated DNA strand breaks (Takebayashi et al., 1999) . Additionally, ET-743 also appears to indirectly disorganize microtubule formation (Garcia-Rocha et al., 1996) . The novelty of the structure, its site of action and its potent in vitro and in vivo activity creates a novel pro®le unique from other existing chemotherapeutics.
One of the hurdles faced by Pharma Mar is the synthesis of ET-743. Currently 1 ton of sea squirt is required to yield 1 g of the drug. Currently 3 g are required for a cycle of treatment. However, the Nobel Prize chemist, Dr EJ Corey, has recently published a synthetic route to make the compound (Martinez and Corey, 2000) . The scale up of this synthesis is currently being planned, which hopefully can provide an economical route to bulk quantities of drug.
ET-743 has recently completed multiple Phase I studies in both the US and Europe where it was given as either a 1 h daily infusion 65, or as a 1 or 3 or 24 or 72 h infusion every 3 weeks. In general, the compound was well tolerated, having linear pharmacokinetic pro®les and was excreted mainly through the urine (Rosing et al., 1998) . In one French trial using the 24 h infusion protocol, 4/24 patients (18%) exhibited tumor regression by more than 50%, which is an impressive ®nding considering that these patients have all previously failed known chemotherapy regimens (Taamma et al., 1999) . Dose limiting side eects included fatigue, thrombocytopenia and neutropenia. All adverse eects were reversible. The maximum tolerated dose was 1800 mg/m 2 , while the recommended therapeutic dose was 1500 mg/m 2 . The 1 h infusion protocol appeared to be less well tolerated and will not be followed in further investigations (Villalona-Calero et al., 1999) . Data from the 3 and 72 h studies are not currently available. ET-743 is presently under Phase II investigation to treat sarcoma. The trials are being coordinated by the EORTC European Osteosarcoma Intergroup.
New antifolates, lometrexol
Lometrexol is an antifolate that inhibits glycinamide ribonucleotide formyltransferase (GARFT) an enzyme involved in purine biosynthesis. The compound has been licensed from Eli Lilly by Tularik. Lometrexol has no direct inhibitory activity on dihydrofolate reductase like other classical antifolate drugs such as methotrexate. Lometrexol is transported into cells by the reduced folate carrier and the folate receptor (see review by Takimoto and Allegra, 1995) . Once inside the cell the agent is a substrate for folylpolyglutamate synthetase (FPGS) and becomes an active inhibitor of two of the nine steps involved in the de novo synthesis of purines, speci®cally GARFT, as well as aminoimidazole carboxamide ribonucleotide transformylase. The polyglutamyl forms are 100-fold more active than the mono-derivatives of GARFT. The degree of polyglutamylation of the antifolates not only dictates potency but also aects the pharmacokinetics and toxicity. FPGS exists in two isoforms, one cytoplasmic the other mitchondrial, and the decrease in enzyme expression is known to be related to antifolate resistance (see review by Kamen, 1997) . Since Lometrexol competes with 5-methyltetrahydrofolate for the folate receptor it can cause folate de®ciency if no concurrent treatments are provided (Pizzorno et al., 1993) . Newer versions of the agent do not require uptake by the folate receptor to enter the cell and hence are less likely to induce this side eect. Modi®cations of folate diet have been shown to change the pharmacokinetics of these agents and thereby aect their toxicity pro®le (Habeck et al., 1998) .
Lometrexol exhibits anti-tumor activity even against cell lines shown to be resistant to other drugs and is active against multiple tumors in vivo (Habeck et al., 1994) . LY309887 is a second generation antifolate being explored by Lilly with greater ecacy, dierent pharmacokinetics and less toxicity (Mendelsohn et al., 1996) .
Lilly undertook a number of Phase I safety studies with weekly infusion of Lometrexol starting in 1988. Lometrexol exhibits biological activity and reported a number of partial responses and one complete response. However, in the early trials several people died after receiving the agent. Upon further examination, it was shown that those patients who took daily folic acid supplements while on the drug tolerated it much better. Neuropathy and myelosuppression were the major dose-limiting side eects reported in these Phase I trials (Ray et al., 1993) . These cumulative side eects were unexpected, as they were not seen in preclinical studies unless the diet was modi®ed to limit the amount of folic acid, which is normally high in animal feeds. It is thought that the dietary folate limits the hepatic accumulation of the drug. After much work to de®ne the optimum schedule for Lometrexol and the supportive folate regimen, Tularik recently initiated Phase II studies in breast cancer, melanoma, non-small cell lung cancer and sarcoma (Scrip, August 25, 2000) .
A protein tyrosine kinase inhibitor, STI-571
In some white blood cells there is a genetic¯aw on the`Philadelphia' chromosome, producing a chimeric BCR/ABL protein, which allows the cells to divide constantly (Nowell and Hungerford, 1960; Rowley, 1973) . Ultimately these white cells crowd out the normal populations leading to severe immune dysfunction. Activation of the BCR/ABL oncogene results in the activation of multiple signaling pathways including an increase in ABL protein tyrosine kinase (PTK). These kinases then modify multiple pathways that aect expression of genes that confer malignant phenotypes including the oligomerization of BCR/ABL (Daley et al., 1987 (Daley et al., , 1990 ). Novartis's BCR-ABL kinase signal inhibitor, STI-571 (formerly CGP 57-148B), competitively blocks the activity of this protein tyrosine kinase by blocking the ATP Figure 1 The seven molecules discussed as potential new therapies binding site on both ABL and BCR/ABL . By occupying the ATP pocket on BCR/ABL, STI-571 inhibits the phosphorylation of tyrosine residues on substrate proteins thereby leaving them inactivated, and blocking signal transduction. This action attenuates cell division of multiple cell types thereby limiting tumor growth. STI-571 can also block the activity of other kinases including platelet-derived growth factor receptor (PDGFR) and stem-cell factor receptor (c-KIT), which also promotes tumor growth.
Inhibition of BCR/ABL PTK leads to apoptosis in leukemic cell lines within a short period of time (within 30 h) whereas its activity in freshly isolated CML samples from patients takes longer (100 h) . Continuous inhibition of PTK also leads to cures in mice bearing BCR/ABL-positive tumors (le Coutre et al., 1999) . However, repeated passage of cultured cells with STI-571 elicits resistance which is likely a result of an overexpression of BCR/ABL in such cells (le Coutre et al., 2000; Weisberg and Grin, 2000) .
Phase I clinical data have made headlines everywhere due to the almost complete remission of all 31/31 earlystage chronic myelogenous leukemia (CML) patients (Druker et al., 1999) . STI-571 was given orally daily until white blood cells counts return to normal levels. The drug was well tolerated, with nausea and vomiting being the prevalent side eects. There have also been several cytogenetic reversals in the Phase I trial, suggesting the possibility of complete eradication of the tumor cells. Some patients have taken the drug for many months now and no evidence of resistance has been reported to date. Although the trials were only started in 1998, there appears to be such a compelling biological and public response that expeditious early approval is being considered. The response of STI-571 in CML patients is unprecedented and hence it is hoped that these studies are replicated with such impressive results.
